BRIEF-Anaptys Announces Intent To Separate Biopharma Operations From Substantial Royalty Assets By Year-End 2026

Reuters

Sep 30

Sept 29 (Reuters) - AnaptysBio Inc ANAB.O:

ANAPTYS ANNOUNCES INTENT TO SEPARATE BIOPHARMA OPERATIONS FROM SUBSTANTIAL ROYALTY ASSETS BY YEAR-END 2026
ANAPTYS ANNOUNCES INTENT TO SEPARATE BIOPHARMA OPERATIONS FROM SUBSTANTIAL ROYALTY ASSETS BY YEAR-END 2026
ANAPTYSBIO INC - BIOPHARMA CO TO FOCUS ON IMMUNOLOGY THERAPEUTICS
ANAPTYSBIO INC - DANIEL FAGA ANTICIPATED TO BE CEO OF BIOPHARMA CO
ANAPTYSBIO INC - UPON DEAL CLOSE, ROYALTY MANAGEMENT COMPANY TO MANAGE ROYALTIES INCLUDING JEMPERLI & IMSIDOLIMAB
ANAPTYSBIO: UPON COMPLETION, BIOPHARMA CO TO LAUNCH WITH ADEQUATE CAPITAL TO FUND OPERATIONS FOR AT LEAST 2 YEARS

Source text: ID:nGNX6VdsNH

Further company coverage: ANAB.O

(((( Reuters.briefs@thomsonreuters.com ;));))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2571661143"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571661143\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571661143?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 06:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571661143","market":"fut","top_or_hot":-1,"title":"BRIEF-Anaptys Announces Intent To Separate Biopharma Operations From Substantial Royalty Assets By Year-End 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Anaptys Announces Intent To Separate Biopharma Operations From Substantial Royalty Assets By Year-End 2026</title></head><body><p><span>Sept 29 (Reuters)</span><span> - </span>AnaptysBio Inc <span>ANAB.O</span>:</p><ul><li><p>ANAPTYS ANNOUNCES INTENT TO SEPARATE BIOPHARMA OPERATIONS FROM SUBSTANTIAL ROYALTY ASSETS BY YEAR-END 2026</p></li><li><p>ANAPTYS ANNOUNCES INTENT TO SEPARATE BIOPHARMA OPERATIONS FROM SUBSTANTIAL ROYALTY ASSETS BY YEAR-END 2026</p></li><li><p>ANAPTYSBIO INC - BIOPHARMA CO TO FOCUS ON IMMUNOLOGY THERAPEUTICS</p></li><li><p>ANAPTYSBIO INC - DANIEL FAGA ANTICIPATED TO BE CEO OF BIOPHARMA CO</p></li><li><p>ANAPTYSBIO INC - UPON DEAL CLOSE, ROYALTY MANAGEMENT COMPANY TO MANAGE ROYALTIES INCLUDING JEMPERLI &amp; IMSIDOLIMAB</p></li><li><p>ANAPTYSBIO: UPON COMPLETION, BIOPHARMA CO TO LAUNCH WITH ADEQUATE CAPITAL TO FUND OPERATIONS FOR AT LEAST 2 YEARS</p></li></ul><p>Source text: <span>ID:nGNX6VdsNH</span></p><p>Further company coverage: <span>ANAB.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Anaptys Announces Intent To Separate Biopharma Operations From Substantial Royalty Assets By Year-End 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Anaptys Announces Intent To Separate Biopharma Operations From Substantial Royalty Assets By Year-End 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-30 06:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Anaptys Announces Intent To Separate Biopharma Operations From Substantial Royalty Assets By Year-End 2026</title></head><body><p><span>Sept 29 (Reuters)</span><span> - </span>AnaptysBio Inc <span>ANAB.O</span>:</p><ul><li><p>ANAPTYS ANNOUNCES INTENT TO SEPARATE BIOPHARMA OPERATIONS FROM SUBSTANTIAL ROYALTY ASSETS BY YEAR-END 2026</p></li><li><p>ANAPTYS ANNOUNCES INTENT TO SEPARATE BIOPHARMA OPERATIONS FROM SUBSTANTIAL ROYALTY ASSETS BY YEAR-END 2026</p></li><li><p>ANAPTYSBIO INC - BIOPHARMA CO TO FOCUS ON IMMUNOLOGY THERAPEUTICS</p></li><li><p>ANAPTYSBIO INC - DANIEL FAGA ANTICIPATED TO BE CEO OF BIOPHARMA CO</p></li><li><p>ANAPTYSBIO INC - UPON DEAL CLOSE, ROYALTY MANAGEMENT COMPANY TO MANAGE ROYALTIES INCLUDING JEMPERLI &amp; IMSIDOLIMAB</p></li><li><p>ANAPTYSBIO: UPON COMPLETION, BIOPHARMA CO TO LAUNCH WITH ADEQUATE CAPITAL TO FUND OPERATIONS FOR AT LEAST 2 YEARS</p></li></ul><p>Source text: <span>ID:nGNX6VdsNH</span></p><p>Further company coverage: <span>ANAB.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUA6P9NZH:1","article_id":"2571661143","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571661143","pubTimestamp":1759184540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Anaptys Announces Intent To Separate Biopharma Operations From Substantial Royalty Assets By Year-End 2026Sept 29 (Reuters) - AnaptysBio Inc ANAB.O:ANAPTYS ANNOUNCES INTENT TO SEPARATE BIOPHARMA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ANAB":"Anaptysbio Inc"},"translate_title":"简介-Anaptys宣布打算在2026年底前将生物制药业务与大量特许权使用费资产分开","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANAB":0.9},"content_text":"BRIEF-Anaptys Announces Intent To Separate Biopharma Operations From Substantial Royalty Assets By Year-End 2026Sept 29 (Reuters) - AnaptysBio Inc ANAB.O:ANAPTYS ANNOUNCES INTENT TO SEPARATE BIOPHARMA OPERATIONS FROM SUBSTANTIAL ROYALTY ASSETS BY YEAR-END 2026ANAPTYS ANNOUNCES INTENT TO SEPARATE BIOPHARMA OPERATIONS FROM SUBSTANTIAL ROYALTY ASSETS BY YEAR-END 2026ANAPTYSBIO INC - BIOPHARMA CO TO FOCUS ON IMMUNOLOGY THERAPEUTICSANAPTYSBIO INC - DANIEL FAGA ANTICIPATED TO BE CEO OF BIOPHARMA COANAPTYSBIO INC - UPON DEAL CLOSE, ROYALTY MANAGEMENT COMPANY TO MANAGE ROYALTIES INCLUDING JEMPERLI & IMSIDOLIMABANAPTYSBIO: UPON COMPLETION, BIOPHARMA CO TO LAUNCH WITH ADEQUATE CAPITAL TO FUND OPERATIONS FOR AT LEAST 2 YEARSSource text: ID:nGNX6VdsNHFurther company coverage: ANAB.O (((( Reuters.briefs@thomsonreuters.com ;));))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}